ENGN Stock Forecast & Price Target

enGene Therapeutics is viewed positively because detalimogene has a credible accelerated-approval path, with management advancing toward BLA submission and a pre-BLA FDA meeting in 4Q26 that could de-risk the regulatory package. Its commercial case is strengthened by a differentiated, non-viral, easy-to-administer profile that may fit resource-constrained community urology practices, where payer feedback suggests coverage could follow NCCN inclusion with 2A support. Although the pivotal dataset is still immature, AUA 2026 showed a 54% CR anytime rate and 25% 12-month CR, and management believes roughly 10% share or about 2,000 patients could support ~$1B in net sales at parity pricing.

enGene Therapeutics is facing a deteriorating fundamental profile because detalimogene’s LEGEND Cohort 1 has underwhelmed on efficacy and durability, with a 39% any-time CR and 32% 6-month CR in the 32 newest patients, pulling the overall any-time CR to 54%, 6-month CR to 43%, and the 12-month CR estimate to 25%, below competitive benchmarks. The company is now dependent on the unproven polidocanol rinse cohort to repair questions about mechanism, drug penetration, and response durability, while management has also reduced workforce by approximately 50% and stopped enrollment in LEGEND Cohorts 2a, 2b, and 3, signaling pressure on execution and capital efficiency. Although cash and marketable securities totaled $285.2M as of April 30, 2026, the lack of formal runway guidance, combined with BLA filing plans in 2H26 and a 2027 approval decision, leaves substantial clinical, regulatory, and financing risk.